Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 290
Filtrar
1.
Clin Exp Dermatol ; 45(2): 207-211, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31361915

RESUMEN

We describe two patients with BRAF-mutated melanoma of the epithelioid cell type arising from primary acquired melanosis with severe atypia of the right bulbar conjunctiva. Patient 1 was a 71-year-old Japanese man. After adjuvant cryotherapy and enucleation of the right eyeball, therapy with vemurafenib was administered for a distant metastasis to a lumbar vertebra, accompanied by erythema multiforme and two keratinous tumours. The patient died due to metastases to the liver and multiple vertebrae, despite therapy with nivolumab and combination therapy with dabrafenib plus trametinib. Patient 2 was a 72-year-old Japanese man. After adjuvant cryotherapy, periodic mitomycin C eye drops, and excision of the superficial portion of the right parotid gland and the dissection of cervical lymph nodes, he was treated with adjuvant combination therapy with dabrafenib plus trametinib. Dermatologists should be familiar with BRAF-mutated conjunctival melanoma, which is usually located on the bulbar conjunctiva and associated with more frequent distant metastasis.


Asunto(s)
Neoplasias de la Conjuntiva/genética , Melanoma/genética , Mutación , Proteínas Proto-Oncogénicas B-raf/genética , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Conjuntiva/patología , Conjuntiva/cirugía , Neoplasias de la Conjuntiva/patología , Neoplasias de la Conjuntiva/terapia , Resultado Fatal , Humanos , Neoplasias Hepáticas/secundario , Metástasis Linfática , Quinasas Quinasa Quinasa PAM/antagonistas & inhibidores , Masculino , Melanoma/patología , Melanoma/secundario , Melanoma/terapia , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas B-raf/antagonistas & inhibidores
5.
Hum Reprod ; 33(7): 1228-1236, 2018 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-29684118

RESUMEN

STUDY QUESTION: Does spontaneous endometriosis in cynomolgus monkeys have the characteristics required of a good experimental model? SUMMARY ANSWER: Spontaneous endometriosis in cynomolgus monkeys exhibited similar clinicopathological characteristics to the human disease and was useful as an experimental model. WHAT IS KNOWN ALREADY: The prevalence of endometriosis in autopsied cynomolgus monkeys (Macaca fascicularis) in a breeding colony was reported to be 28.7% in 1993. The histopathological findings we reported recently showed that components of spontaneous endometriosis were not only endometriotic epithelium and stromal cells (CD10-positive) with hemorrhage and inflammation, but also smooth muscle metaplasia and nerve fibers. STUDY DESIGN, SIZE, DURATION: During routine medical examinations at a research facility from 2008 to 2012, 614 female cynomolgus monkeys of reproductive age (6-25 years) were screened for endometriosis by the presence of regular menstrual bleeding, serum CA125 levels and palpation of the abdomen. In total, 29 monkeys were selected as subjects for the following study. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of the 29 monkeys selected, 15 were diagnosed with endometriosis by laparoscopy and/or open surgery. The monkeys were monitored by observing their general condition, and eight of these were monitored using laparoscopy and MRI. In addition, to investigate appropriate screening parameters and endometriosis-associated biological parameters in monkeys, we retrospectively examined general laboratory parameters that correlate to the menstrual cycle and disease status. MAIN RESULTS AND THE ROLE OF CHANCE: The combination of CA125 serum levels (this was a useful marker for chocolate cysts), palpation of the abdomen, and fecal abnormalities was the most efficient screening method for diagnosing monkeys with endometriosis. Each animal could be diagnosed and assigned a disease stage by laparoscopy. While monitoring the disease stage by laparoscopy and/or MRI, disease status in individual monkeys was mainly stable or was progressive for 2-7 months. The detection rate by screening was low (15/614) but age-specific analysis suggests that screening would be more efficient if a colony for an endometriosis model is maintained with 11-20-year olds. As an endometriosis-associated biological parameter, the decrease in food consumption that coincided with menstruation was selected and correlated well (R2 value = 0.8239) with disease status (according to a modified adhesion revised American Fertility Society score). LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Peritoneal fluid was not analyzed because a smaller amount is produced in cynomolgus monkeys than in baboons. Although clinical endometriosis-associated pain is evaluated in women using a visual analog scale, pain could not be directly evaluated in this non-human primate model. WIDER IMPLICATIONS OF THE FINDINGS: Although cynomolgus monkeys are relatively small (2-5 kg) primates, laparoscopy and MRI make it possible to evaluate spontaneous endometriosis in these monkeys and to monitor its development over time. Spontaneous endometriosis in cynomolgus monkeys is a useful model for evaluating disease progress and drug efficacy because they have similar lesions to those in humans, and conventional laboratory methods and parameters for assessment are well established. STUDY FUNDING/COMPETING INTEREST(S): No external funds were used for this study. A.N.-K., K.T., H.T., A.K. and M.S. are full-time employees of Chugai Pharmaceutical Co., Ltd. R.K. received a consultancy fee from Chugai Pharmaceutical Co., Ltd. and lecture fees from Chugai Pharmaceuticals, Japan Vaccine Co. Ltd., Merck & Co., Mochida Co. Ltd., Roche Diagnostics, and BD, unrelated to the submitted work. S.N., S.O. and T.S. have nothing to declare.


Asunto(s)
Modelos Animales de Enfermedad , Endometriosis/patología , Animales , Líquido Ascítico/patología , Femenino , Macaca fascicularis , Estudios Retrospectivos , Células del Estroma/patología
6.
Sci Rep ; 4: 6849, 2014 Oct 30.
Artículo en Inglés | MEDLINE | ID: mdl-25355408

RESUMEN

Impact ionization (IMP) is a fundamental process in semiconductors, which results in carrier multiplication through the decay of a hot electron into a low-energy state while generating an electron-hole pair. IMP is essentially a state selective process, which is triggered by electron-electron interaction involving four electronic states specified precisely by energy and momentum conservations. However, important state-selective features remain undetermined due to methodological limitations in identifying the energy and momentum of the states involved, at sufficient temporal resolution, to reveal the fundamental dynamics. Here we report state-resolved ultrafast hot electron dynamics of IMP in InSb, a semiconductor with the lowest band-gap energy. The ultrafast decay of state-resolved hot-electron populations and the corresponding population increase at the conduction band minimum are directly captured, and the rate of IMP is unambiguously determined. Our analysis, based on the direct knowledge of state-resolved hot electrons, provides far deeper insight into the physics of ultrafast electron correlation in semiconductors.

7.
Clin Dev Immunol ; 2012: 582716, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22966239

RESUMEN

Chronic hepatitis C (CHC) is a serious medical problem necessitating more effective treatment. This study investigated the hypothesis that an induction approach with nIFN-beta for 24 weeks followed by PEG-IFN-alpha+ribavirin (standard of care: SOC) for 48 weeks (novel combination treatment: NCT) would increase the initial virologic response rate and restore innate and adaptive immune responses in CHC. Seven CHC patients with a high viral load and genotype 1b were treated with NCT. Serum cytokine and chemokine levels were evaluated during NCT. NCT prevented viral escape and breakthrough resulting in persistent viral clearance of HCVRNA. IL-15 was increased at the end of induction therapy in both early virologic responders (EAVRs) and late virologic responders (LAVRs); CXCL-8, CXCL-10, and CCL-4 levels were significantly decreased (P < 0.05) in EAVR but not in LAVR during NCT, and IL-12 increased significantly (P < 0.05) and CXCL-8 decreased significantly (P < 0.05) after the end of NCT in EAVR but not in LAVR. NCT prevented viral breakthrough with viral clearance leading to improvement of innate and adaptive immunity resulting in a sustained virologic response (SVR). NCT (n = 8) achieved a higher SVR rate than SOC (n = 8) in difficult-to-treat CHC patients with genotype 1 and high viral loads.


Asunto(s)
Inmunidad Adaptativa/efectos de los fármacos , Antivirales/uso terapéutico , Hepacivirus/efectos de los fármacos , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/inmunología , Inmunidad Innata/efectos de los fármacos , Interferón beta/uso terapéutico , Adulto , Anciano , Quimiocinas/sangre , Citocinas/sangre , Quimioterapia Combinada , Femenino , Hepacivirus/inmunología , Hepatitis C Crónica/virología , Humanos , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Polietilenglicoles/uso terapéutico , ARN Viral/sangre , Proteínas Recombinantes/uso terapéutico , Ribavirina/uso terapéutico , Resultado del Tratamiento , Carga Viral/efectos de los fármacos
8.
Aliment Pharmacol Ther ; 20 Suppl 1: 90-4, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15298612

RESUMEN

BACKGROUND: Biliary tract cancer is a highly fatal disease with poor prognosis, but the aetiology is poorly understood. AIM: We aimed to identify Helicobacter bilis infection in the gallbladder in patients with biliary tract disease. METHODS: Archival gallbladder specimens from 34 patients (14 males and 20 females) with an average age of 61.4 +/- 12.2 years (mean +/- SE) were retrieved, consisting of 11 cases of gallbladder cancer, three of bile duct cancer, 16 of cholecystolithiasis and four of pancreatic cancer. DNA was extracted and nested PCR using primers specific for 16S rRNA of H. bilis was performed. RESULTS: Amplification was observed in 3 of 11 gallbladder cancer cases (27.2%) and one of three cases with biliary duct cancer (33.3%). In total, four of 14 cases with biliary tract cancer were positive for H. bilis (28.6%). In addition, the presence of H. bilis was shown in two of 16 cases (12.5%) with cholecystolithiasis. Notably, although the number of cases examined was small, none of the four cases with pancreatic cancer showed the presence of H. bilis infection in the gallbladder without apparent abnormalities. CONCLUSION: H. bilis infection may play a role in biliary tract disease, particularly in biliary tract cancer.


Asunto(s)
Neoplasias del Sistema Biliar/microbiología , Enfermedades de la Vesícula Biliar/microbiología , Infecciones por Helicobacter/complicaciones , ADN Bacteriano/aislamiento & purificación , Femenino , Helicobacter/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Técnicas de Amplificación de Ácido Nucleico , Reacción en Cadena de la Polimerasa/métodos
9.
Br J Cancer ; 88(4): 530-6, 2003 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-12592366

RESUMEN

Mutations of codon 12 in the Ki-ras gene are frequently found in pancreatic and colorectal cancers. It has been demonstrated that human T-cells have the potential to recognise tumours expressing mutated ras-derived peptides. However, it remains unclear whether T-cells from a given individual can recognise the mutant peptides, which are expressed in that individual's tumour tissues. Mutations of the Ki-ras oncogene were analysed by the mutant-allele-specific amplification (MASA) method in pancreatic and colorectal tumour tissues, and T-cell responses against mutated Ki-ras-derived peptides were measured by [(3)H]thymidine incorporation and IFN-gamma production assays. Specific T-cell responses against Ki-ras-products were found in cancer patients, whereas no immune response was observed in normal individuals (P<0.01). Six of the eight pancreatic cancer patients (75%) and nine of 26 colorectal cancer patients (35%) had T-cell responses to mutated Ki-ras-derived-peptides. T-cell response in a given individual cannot recognise the same mutated ras peptide, which is expressed in that individual's tumour tissues. However, pancreatic and colorectal cancer patients have T-cell immunity against Ki-ras-peptides, and this provides potential target for cancer immunotherapy.


Asunto(s)
Neoplasias Colorrectales/inmunología , Neoplasias Pancreáticas/inmunología , Proteínas Proto-Oncogénicas/inmunología , Linfocitos T/inmunología , División Celular , Neoplasias Colorrectales/genética , Antígenos HLA-DQ/genética , Antígenos HLA-DQ/inmunología , Antígenos HLA-DR/genética , Antígenos HLA-DR/inmunología , Humanos , Interferón gamma/metabolismo , Activación de Linfocitos , Mutación , Neoplasias Pancreáticas/genética , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas p21(ras) , Proteínas ras
10.
J Comp Pathol ; 127(2-3): 223-7, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12354537

RESUMEN

Basal cell carcinoma with folliculoapocrine differentiation was diagnosed in a male Cape clawless otter (Aonyx capensis) aged >8 years. A tumour mass in the left submandibular region was removed surgically, but another tumour subsequently appeared on the left cheek. In addition, necropsy revealed a subcutaneous tumour mass at the excision site. Histologically, the tumours consisted of lobules or islands of basaloid cells, frequently with central keratinization and tubular structures. The presence of isthmic keratinization and apocrine differentiation was confirmed by immunolabelling for cytokeratins, and a few cytokeratin-positive tumour cells were found in a submandibular lymph node. The neoplasm, characterized by its metachronous and recurrent nature, metastasis to the local lymph node and amyloidosis, closely resembled human differentiated basal cell carcinoma, both clinically and pathologically.


Asunto(s)
Carcinoma Basocelular/veterinaria , Nutrias , Neoplasias Cutáneas/veterinaria , Animales , Biomarcadores de Tumor/metabolismo , Carcinoma Basocelular/metabolismo , Carcinoma Basocelular/secundario , Carcinoma Basocelular/cirugía , Resultado Fatal , Inmunohistoquímica/veterinaria , Queratinas/metabolismo , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/patología , Metástasis Linfática/patología , Masculino , Neoplasias Primarias Secundarias , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/cirugía
11.
Arch Surg ; 136(12): 1410-4, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11735870

RESUMEN

HYPOTHESIS: Hepatic portal venous gas (HPVG) has been considered a rare entity associated with a grave prognosis. Since 1978, when Liebman et al reviewed 64 cases of HPVG and reported a mortality of 75%, the number of reported cases has been increasing. DESIGN: Case series. PATIENTS AND METHODS: We reviewed the literature on 182 cases of HPVG in adults, including 4 of our patients, (transplantation and abdominal trauma cases were excluded) and analyzed the cause, pathogenesis, and clinical features. RESULTS: In this series, the underlying clinical events associated with HPVG were bowel necrosis (43%), digestive tract dilatation (12%), intraperitoneal abscess (11%), ulcerative colitis (4%), gastric ulcer (4%), Crohn disease (4%), complications of endoscopic procedures (4%), intraperitoneal tumor (3%), and other (15%). The overall mortality was 39% but varied depending on the underlying disease. CONCLUSIONS: Hepatic portal venous gas is a lethal or curable entity caused by various diseases. The underlying disease associated with HPVG determines the clinical features and prognosis of the patients. The treatment of patients with HPVG should be directed to the underlying disease.


Asunto(s)
Gases , Venas Hepáticas , Anciano , Neoplasias del Colon/complicaciones , Femenino , Humanos , Intestinos/patología , Masculino , Persona de Mediana Edad , Necrosis
12.
Int J Pancreatol ; 29(1): 53-8, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11558633

RESUMEN

BACKGROUND: Adenosquamous carcinoma of the pancreas is a rare tumor with an extremely poor survival rate. No obvious evidence that multidisciplinary treatments improves the prognosis and survival has been reported. PATIENT AND RESULTS: A 63-yr-old female with adenosquamous carcinoma of the pancreas underwent extended radical surgery, intraoperative radiation therapy, postoperative intraarterial chemotherapy, and external beam radiation therapy. The patient is alive at 40 mo after surgery with no recurrence. CONCLUSIONS: Multidisciplinary treatments including aggressive surgery, intraoperative radiation therapy, and locoregional chemotherapy might improve the survival of patients with adenosquamous carcinoma of the pancreas to inhibit liver metastasis and local recurrence.


Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Adenoescamoso/radioterapia , Carcinoma Adenoescamoso/cirugía , Neoplasias Pancreáticas/radioterapia , Neoplasias Pancreáticas/cirugía , Carcinoma Adenoescamoso/tratamiento farmacológico , Terapia Combinada , Femenino , Humanos , Cuidados Intraoperatorios , Persona de Mediana Edad , Neoplasias Pancreáticas/tratamiento farmacológico , Cuidados Posoperatorios
13.
Cancer Res ; 61(16): 6158-62, 2001 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-11507067

RESUMEN

Tumor-specific gene delivery is crucial to achieving successful effects in suicide gene therapy. Carcinoembryonic antigen (CEA) promoter has been widely used for this purpose, but the expression level of tumor-specific promoters such as CEA promoter is generally low. In the previous study, we used the Cre/loxP system and showed that LacZ expression by the CEA promoter was remarkably enhanced and maintained its specificity using the Cre/loxP regulation system. In this study, the Cre/loxP system was first applied to augmentation of selective expression of the cytosine deaminase (CD) gene as a suicide gene therapy in CEA-producing cells. The double infection with AxCEANCre expressing Cre recombinase under the control of the CEA promoter and AxCALNLCD expressing the CD gene under the control of the CAG promoter by the Cre switching system rendered CEA-producing tumor cells 13-fold more sensitive to 5-fluorocytosine (5-FC) compared with the single infection with AxCEACD expressing CD gene driven by the CEA promoter. The therapeutic efficacy of the enhanced CD/5-FC suicide gene therapy was evaluated in orthotopic implantation models of human gastric carcinoma. Adenovirus vectors (1 x 10(9) plaque-forming units) were administered i.p. into mice three times, and then 5-FC was administered i.p. for the next 10 days. Tumor volume and weight in mice treated with AxCEANCre and AxCALNLCD/5-FC were significantly reduced as compared with those in mice treated not only with Mock (AxCALacZ) but also with AxCEACD/5-FC (P < 0.0001). This beneficial effect on tumor burden was also reflected in the overall survival. The survival periods of the mice treated with AxCEANCre and AxCALNLCD/5-FC were longer than those of mice treated with Mock or AxCEACD/5-FC (P < 0.01). These results suggested that application of the Cre/loxP system could provide a new approach for enhanced selective suicide gene therapy of CD/5-FC for the treatment of advanced gastric carcinoma.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Antígeno Carcinoembrionario/genética , Flucitosina/farmacología , Terapia Genética/métodos , Nucleósido Desaminasas/genética , Neoplasias Gástricas/terapia , Adenoviridae/genética , Animales , Antimetabolitos Antineoplásicos/farmacocinética , Antígeno Carcinoembrionario/biosíntesis , Citosina Desaminasa , Femenino , Flucitosina/farmacocinética , Expresión Génica , Vectores Genéticos/genética , Células HeLa , Humanos , Integrasas/genética , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Nucleósido Desaminasas/metabolismo , Regiones Promotoras Genéticas/genética , Neoplasias Gástricas/genética , Neoplasias Gástricas/inmunología , Células Tumorales Cultivadas , Proteínas Virales/genética
14.
Oncology ; 61(1): 16-22, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11474243

RESUMEN

TS-1(S-1) has been developed as a new oral anticancer drug based on the biological modulation of 5-fluorouracil. We treated a patient with highly advanced gastric carcinoma with a new combination chemotherapy of S-1 and low-dose cisplatin. Remarkable tumor reduction was observed after two cycles of this therapy in the primary tumor and metastatic lymph nodes, and the ascites disappeared. This was concluded to be a partial response. The only adverse effect was skin pigmentation of the fingers (grade 1), leading to early timing of operation after chemotherapy. The gastric tumor showed evident invasion to the serosa. Lymph nodes around the stomach were swollen. Peritoneal dissemination was also recognized in the omentum and mesocolon. Total gastrectomy with regional lymph node dissection was performed. Disseminated tumors were all resected. Histological examination showed that no tumor cells were detected in the gastric primary lesion, metastatic lymph nodes or disseminated peritoneal tumors, suggesting pathological complete remission. It was suggested that this regimen could be a potent combined therapy for the treatment of patients with highly advanced gastric carcinoma, and it could be useful as neoadjuvant chemotherapy. Further studies are necessary to evaluate the efficacy of this therapy.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Gastrectomía , Neoplasias Peritoneales/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Adenocarcinoma/secundario , Adenocarcinoma/cirugía , Antimetabolitos Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Cisplatino/administración & dosificación , Combinación de Medicamentos , Gastroscopía , Humanos , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Ácido Oxónico/administración & dosificación , Neoplasias Peritoneales/secundario , Neoplasias Peritoneales/cirugía , Piridinas/administración & dosificación , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía , Tegafur/administración & dosificación , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
17.
Br J Cancer ; 84(8): 1052-7, 2001 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-11308253

RESUMEN

Mutations in the p53 gene are the most common genetic alterations found in human tumours, and these mutations result in high levels of p53 protein in the tumour cells. Since the expression levels of wild-type p53 in nonmalignant tissue are usually much lower in contrast, the p53 protein is an attractive target for cancer immunotherapy. We tested p53 encoded HLA-A24 binding peptides for their capacity to elicit anti-tumour cytotoxic T lymphocytes (CTL) in vitro. These peptides were in murine p53-derived cytotoxic peptides, which were being presented to CTL by H-2K(d)and H-2K(b)molecules, because the HLA-A24 peptide binding motifs were similar to the H-2K(d)and H-2K(b). For CTL induction, we used CD8(+)T lymphocytes from the peripheral blood mononuclear cells (PBMC) of healthy donors and the peptides from pulsed dendritic cells as antigen-presenting cells. We identified the peptide, p53-161 (AIYKQSQHM), which was capable of eliciting CTL lines that lysed tumour cells expressing HLA-A24 and p53. The effectors lysed C1RA24 cells (p53(+), HLA-A*2402 transfectant), but not their parental cell lines C1R (p53(+), HLA-A,B null cell). These results strongly indicate that the CTL exerts cytotoxic activity in HLA-A24's restricted manner. The identification of this novel p53 epitope for CTL offers the possibility to design and develop specific immunotherapeutic approaches for treating tumours with p53 mutation in HLA-A24-positive patients.


Asunto(s)
Epítopos/inmunología , Antígenos HLA-A/inmunología , Linfocitos T Citotóxicos/inmunología , Proteína p53 Supresora de Tumor/inmunología , Animales , Unión Competitiva , Línea Celular , Células Cultivadas , Pruebas Inmunológicas de Citotoxicidad , Citotoxicidad Inmunológica , Epítopos/química , Antígenos HLA-A/metabolismo , Antígeno HLA-A24 , Células HT29 , Humanos , Células K562 , Ratones , Oligopéptidos/química , Oligopéptidos/inmunología , Oligopéptidos/metabolismo , Unión Proteica , Linfocitos T Citotóxicos/citología , Linfocitos T Citotóxicos/metabolismo , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/química , Proteína p53 Supresora de Tumor/metabolismo
18.
Anticancer Res ; 21(1A): 137-43, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11299727

RESUMEN

The differential expression of hundreds of tightly, transcriptionally controlled genes in isolated human colorectal cancer and respective normal mucosa from two patients was analyzed by the cDNA macroarray technique. mRNA prepared from the colorectal cancer tumors was compared with 588 genes spotted onto the filter. Case A showed down-regulation of the expression of cell-cycle-related genes including cyclins, cyclin-dependent kinase (CDK) 2, and CDK-activating kinase, as compared with normal mucosa from the same patient. The tumors showed up-regulation of expression of angiogenesis-related genes such as type II cytoskeletal 8 keratin, metalloproteinase subtypes, VEGF, and bFGF, to over 5-fold the levels in normal mucosa. Thus, colorectal carcinoma tissues are characterized by the upregulation of molecules related with angiogenesis. These results suggest that angiogenesis-related molecules are suitable candidates for target-based therapies for colorectal cancer patients. In case B, the largest difference in expression between the tumor and mucosal tissues was observed in the MMP-1 gene. In contrast to the first case, there was no increase in expression of angiogenesis-related molecules or decrease in expression of cell-cycle-regulatory molecules. The expression profile was quite different between these two patients. This approach may eventually provide a mean of selecting target-based drugs in individual colon cancer patients.


Asunto(s)
Carcinoma/genética , Proteínas de Ciclo Celular/genética , Neoplasias Colorrectales/genética , Regulación Neoplásica de la Expresión Génica , Neovascularización Patológica , Análisis de Secuencia por Matrices de Oligonucleótidos , Adulto , Anciano , Carcinoma/irrigación sanguínea , Carcinoma/metabolismo , Proteínas de Ciclo Celular/biosíntesis , Neoplasias Colorrectales/irrigación sanguínea , Neoplasias Colorrectales/metabolismo , Regulación hacia Abajo , Perfilación de la Expresión Génica , Sustancias de Crecimiento/biosíntesis , Sustancias de Crecimiento/genética , Humanos , Mucosa Intestinal/metabolismo , Queratinas/biosíntesis , Queratinas/genética , Masculino , Metaloendopeptidasas/biosíntesis , Metaloendopeptidasas/genética , ARN Mensajero/biosíntesis , Regulación hacia Arriba
19.
Hepatogastroenterology ; 48(37): 250-2, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11268977

RESUMEN

Biliary cystadenocarcinoma of the liver is a relatively rare disease. Herein, we reported a case of biliary cystadenocarcinoma with a review of the literature. A 71-year-old female was admitted with the chief complaint of epigastralgia. The imaging studies revealed a biliary cystadenocarcinoma in the left hepatic lobe with suspicion of direct invasion to the left and middle hepatic veins and inferior vena cava. However, there was no direct invasion of the tumor to these veins in operation findings, and an extended left hepatic resection was performed without resection of inferior vena cava. The tumor was histologically diagnosed as biliary cystadenocarcinoma of the liver. Diagnosis of biliary cystadenocarcinoma is usually difficult preoperatively, however, a diagnosis was possible with the use of imaging studies. It was suggested that this tumor originated from a benign cystadenoma because of the existence of a transitional zone between normal cells and atypical cells in the cystic wall. Systematic hepatectomy was recommended as the initial treatment in consideration of the features of cystadenocarcinoma.


Asunto(s)
Cistadenocarcinoma/diagnóstico , Neoplasias Hepáticas/diagnóstico , Anciano , Neoplasias de los Conductos Biliares/diagnóstico , Neoplasias de los Conductos Biliares/patología , Neoplasias de los Conductos Biliares/cirugía , Conductos Biliares Intrahepáticos , Cistadenocarcinoma/patología , Cistadenocarcinoma/cirugía , Cistoadenoma/patología , Cistoadenoma/cirugía , Diagnóstico Diferencial , Femenino , Hepatectomía , Humanos , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/cirugía
20.
Br J Cancer ; 84(1): 94-9, 2001 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-11139320

RESUMEN

HER2 / neu is a potential antigen candidate for immunotherapy because of its correlation to a poor prognosis and high expressions in many kinds of epithelial tumours. Especially in the colorectal carcinomas, the higher expression of HER2 / neu is recognized in metastatic regions as well as in primary sites. Several CTL epitopes restricted by HLA-A2.1 and -A3 were identified so far, however epitopes restricted by HLA-A24, that is one of the most common allele in Japanese and Caucasians, have not been identified. In this paper, we showed identification of a CTL epitope peptide of HER2 / neu restricted by HLA-A24. HLA-A24 binding peptides selected by an analysis based on HLA-A24 binding motifs were determined for their binding affinities to HLA-A24 molecules. The peptide with a sequence of RWGLLLALL (position 8-16) named HE1 showed the highest affinity. We induced CTLs from CD8(+)cells of HLA-A24 healthy donors by stimulation with HE1-pulsed autologous dendritic cells. The CTLs showed cytotoxic activity against not only the peptide-pulsed target cells but also HLA-A24 colorectal tumour cell lines that endogenously overexpressed HER2 / neu. The antigen-specificity was confirmed by cold target inhibition assay using HE1-pulsed target cells. In summary, HER2 / neu peptide, RWGLLLALL, may contribute to the induction of antitumour immunity with the peptide-based immunotherapy for the colorectal carcinomas.


Asunto(s)
Neoplasias Colorrectales/terapia , Células Dendríticas/inmunología , Mapeo Epitopo/métodos , Antígenos HLA-A/inmunología , Inmunoterapia , Receptor ErbB-2/inmunología , Linfocitos T/inmunología , Antígeno HLA-A24 , Humanos , Mapeo Peptídico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...